1. |
Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic mark in non-small-cell lung cancer patients undergoing chemotherapy [J]. J Clin Oncol, 2004,22(20):4157-4164.
|
2. |
Schlechte HH, Stelzer C, Weickmann S, et al. TP53 gene in blood plasma DNA of tumor patients [J]. Ann NY Acad Sci,2004, 1022(6):61-69.
|
3. |
Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l’homme [J]. CR Acad Sci Paris, 1948, 142:241-243.
|
4. |
Leon SA, Shapiro B, Sklarof DM, et a1. Free DNA in the serum of cancer patients and the efect of thempy [J]. Cancer Res,1977, 37(3): 646-650..
|
5. |
Vaart MVD, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? [J]. Clinical Biochemistry, 2010, 43(1): 26-36.
|
6. |
黃朝暉, 胡瑜, 華東, 等. 定量PCR 檢測肝細胞癌患者循環血漿DNA 及其臨床意義 [J]. 中國癌癥雜志, 2010, 20(9):663-667.
|
7. |
Jackson PE, Qian GS, Friesen MD, et al. Specific p53 mutations detection in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry [J]. Cancer Res, 2001, 61(1):33-35.
|
8. |
Chang YC, Ho CL, Chen HHW, et al. Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum [J]. Brit J Cancer, 2002, 87(12): 1449-1453.
|
9. |
Board RE, Williams VS, Knight L, et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer [J]. Ann NY Acad Sci, 2008, 1137(8): 98-107.
|
10. |
Chan KC, Yeung SW, Lui WB, et al. Effects of preanalytical factors on the molecular size of cell-free DNA in blood [J]. Clin Chem, 2005, 51(4):781-784.
|
11. |
Thierry AR, Mouliere F, Gongora C, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts [J]. Nucleic Acids Res, 2010, 38(18): 6159-6175.
|
12. |
張敬杰, 歐陽濤, 萬文徽, 等. 乳腺癌患者外周血漿中游離的腫瘤相關DNA 檢測及其臨床價值 [J]. 中華腫瘤雜志, 2007,29(8): 609-613.
|
13. |
Iyer P, Zekri AR, Hung CW, et al. Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients [J]. Exp Mol Pathol, 2010, 88(1):107-111.
|
14. |
Wong IH, Lo YM, Zhang J , et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients [J].Cancer Res, 1999, 59(1): 71-73.
|
15. |
An Q, Liu Y, Gao Y, et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients [J]. Cance Lett, 2002, 188(1): 109-114.
|
16. |
Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer [J]. Clin Cancer Res, 2005,11(3): 1219-1225.
|
17. |
Chang H, Yi B, Li L, et al. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients [J]. Exp Mol Pathol, 2008, 85(2): 96-100.
|
18. |
Leerapun A, Suravarapu SV, Bida JP, et al. The utility of lens culinaris agglutinin reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma:evaluation in a United States referral population [J]. Clin Gastroenterol Hepatol, 2007, 5(3): 394-402..
|
19. |
Nakagawa T, Seki T, Shiro T, et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist Ⅱ and alpha-fetoprotein in hepatocellular carcinoma [J]. Int J Oncol,1999, 14(2) : 281-286.
|
20. |
Nishida N, Nagasaka T, Nishimura T, et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma [J]. Hepatology,2008, 47(3): 908-918.
|
21. |
Shim YH, Yoon GS, Choi HJ, et al. p16 Hypermethylation in the early stage of hepatitis B virus associatedhepatocarcinogenesis [J]. Cancer Lett, 2003, 190(2): 213-219.
|